Taking one step backward to take two steps forward: The importance of breast tumor phenotype in MRI-based prediction of response

Enida Bufi, Paolo Belli, Maria Rosignuolo, Federica Petta, Cristina Grippo, Pierluigi Rinaldi, Michela Giuliani, Maurizio Romani, Gianluca Franceschini, Riccardo Manfredi

Research output: Contribution to journalShort survey

Abstract

Evaluation of tumor phenotype is currently accepted to guide management of breast cancer and neoadjuvant chemotherapy (NAC). Magnetic resonance imaging (MRI) is a diagnostic imaging tool to evaluate response to NAC, mainly through morphological evaluation (RECIST criteria). It has been suggested that the capability of post-NAC MRI in the detection of complete response is greatly influenced by tumor phenotype; the interplay of the expression of estrogen and progesterone receptors and of human epidermal growth factor-2 affects deeply variable tissue characteristics. The purpose of the present review is to revise current evidence about the differential diagnostic performance of MRI according to breast tumor phenotype, both in the post-NAC setting (detection of complete response) and in the pre-NAC settings (prediction of complete response), in order to advise the radiologist in the cautious interpretation of MRI-derived information. We also discuss the potential role of additional MRI techniques [diffusion-weighted imaging (DWI)] in this context. The conclusions of the present review may be helpful to achieve further personalization of management protocols to individual patients.

Original languageEnglish
Pages (from-to)S424-S432
JournalTranslational Cancer Research
Volume7
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Magnetic Resonance Imaging
Breast Neoplasms
Phenotype
Drug Therapy
Diffusion Magnetic Resonance Imaging
Progesterone Receptors
Diagnostic Imaging
Epidermal Growth Factor
Estrogen Receptors
Neoplasms

Keywords

  • Breast MRI
  • Breast tumor phenotype
  • Diffusion-weighted imaging (DWI)
  • Neoadjuvant chemotherapy (NAC)

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Taking one step backward to take two steps forward : The importance of breast tumor phenotype in MRI-based prediction of response. / Bufi, Enida; Belli, Paolo; Rosignuolo, Maria; Petta, Federica; Grippo, Cristina; Rinaldi, Pierluigi; Giuliani, Michela; Romani, Maurizio; Franceschini, Gianluca; Manfredi, Riccardo.

In: Translational Cancer Research, Vol. 7, 01.04.2018, p. S424-S432.

Research output: Contribution to journalShort survey

Bufi, Enida ; Belli, Paolo ; Rosignuolo, Maria ; Petta, Federica ; Grippo, Cristina ; Rinaldi, Pierluigi ; Giuliani, Michela ; Romani, Maurizio ; Franceschini, Gianluca ; Manfredi, Riccardo. / Taking one step backward to take two steps forward : The importance of breast tumor phenotype in MRI-based prediction of response. In: Translational Cancer Research. 2018 ; Vol. 7. pp. S424-S432.
@article{82f444770d2f4ffdb2467d3b59df99dc,
title = "Taking one step backward to take two steps forward: The importance of breast tumor phenotype in MRI-based prediction of response",
abstract = "Evaluation of tumor phenotype is currently accepted to guide management of breast cancer and neoadjuvant chemotherapy (NAC). Magnetic resonance imaging (MRI) is a diagnostic imaging tool to evaluate response to NAC, mainly through morphological evaluation (RECIST criteria). It has been suggested that the capability of post-NAC MRI in the detection of complete response is greatly influenced by tumor phenotype; the interplay of the expression of estrogen and progesterone receptors and of human epidermal growth factor-2 affects deeply variable tissue characteristics. The purpose of the present review is to revise current evidence about the differential diagnostic performance of MRI according to breast tumor phenotype, both in the post-NAC setting (detection of complete response) and in the pre-NAC settings (prediction of complete response), in order to advise the radiologist in the cautious interpretation of MRI-derived information. We also discuss the potential role of additional MRI techniques [diffusion-weighted imaging (DWI)] in this context. The conclusions of the present review may be helpful to achieve further personalization of management protocols to individual patients.",
keywords = "Breast MRI, Breast tumor phenotype, Diffusion-weighted imaging (DWI), Neoadjuvant chemotherapy (NAC)",
author = "Enida Bufi and Paolo Belli and Maria Rosignuolo and Federica Petta and Cristina Grippo and Pierluigi Rinaldi and Michela Giuliani and Maurizio Romani and Gianluca Franceschini and Riccardo Manfredi",
year = "2018",
month = "4",
day = "1",
doi = "10.21037/tcr.2017.09.46",
language = "English",
volume = "7",
pages = "S424--S432",
journal = "Translational Cancer Research",
issn = "2218-676X",
publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Taking one step backward to take two steps forward

T2 - The importance of breast tumor phenotype in MRI-based prediction of response

AU - Bufi, Enida

AU - Belli, Paolo

AU - Rosignuolo, Maria

AU - Petta, Federica

AU - Grippo, Cristina

AU - Rinaldi, Pierluigi

AU - Giuliani, Michela

AU - Romani, Maurizio

AU - Franceschini, Gianluca

AU - Manfredi, Riccardo

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Evaluation of tumor phenotype is currently accepted to guide management of breast cancer and neoadjuvant chemotherapy (NAC). Magnetic resonance imaging (MRI) is a diagnostic imaging tool to evaluate response to NAC, mainly through morphological evaluation (RECIST criteria). It has been suggested that the capability of post-NAC MRI in the detection of complete response is greatly influenced by tumor phenotype; the interplay of the expression of estrogen and progesterone receptors and of human epidermal growth factor-2 affects deeply variable tissue characteristics. The purpose of the present review is to revise current evidence about the differential diagnostic performance of MRI according to breast tumor phenotype, both in the post-NAC setting (detection of complete response) and in the pre-NAC settings (prediction of complete response), in order to advise the radiologist in the cautious interpretation of MRI-derived information. We also discuss the potential role of additional MRI techniques [diffusion-weighted imaging (DWI)] in this context. The conclusions of the present review may be helpful to achieve further personalization of management protocols to individual patients.

AB - Evaluation of tumor phenotype is currently accepted to guide management of breast cancer and neoadjuvant chemotherapy (NAC). Magnetic resonance imaging (MRI) is a diagnostic imaging tool to evaluate response to NAC, mainly through morphological evaluation (RECIST criteria). It has been suggested that the capability of post-NAC MRI in the detection of complete response is greatly influenced by tumor phenotype; the interplay of the expression of estrogen and progesterone receptors and of human epidermal growth factor-2 affects deeply variable tissue characteristics. The purpose of the present review is to revise current evidence about the differential diagnostic performance of MRI according to breast tumor phenotype, both in the post-NAC setting (detection of complete response) and in the pre-NAC settings (prediction of complete response), in order to advise the radiologist in the cautious interpretation of MRI-derived information. We also discuss the potential role of additional MRI techniques [diffusion-weighted imaging (DWI)] in this context. The conclusions of the present review may be helpful to achieve further personalization of management protocols to individual patients.

KW - Breast MRI

KW - Breast tumor phenotype

KW - Diffusion-weighted imaging (DWI)

KW - Neoadjuvant chemotherapy (NAC)

UR - http://www.scopus.com/inward/record.url?scp=85045878834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045878834&partnerID=8YFLogxK

U2 - 10.21037/tcr.2017.09.46

DO - 10.21037/tcr.2017.09.46

M3 - Short survey

AN - SCOPUS:85045878834

VL - 7

SP - S424-S432

JO - Translational Cancer Research

JF - Translational Cancer Research

SN - 2218-676X

ER -